Cyclosporine-Induced Hypertension and Hyperlipidemia: A Practical Guide for Advanced Practice Providers

ALEXIS GEPPNER, MLS, CTTS, MPAS, PA-C

From Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

Author's disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Alexis Geppner, 1515 Holcombe Blvd, Houston, TX 77030

E-mail: ageppner@mdanderson.org

https://doi.org/10.6004/jadpro.2026.17.7.33

© 2026 BroadcastMed LLC

Abstract

Cyclosporine A (CsA) is a widely used calcineurin inhibitor essential for immunosuppression in solid organ and hematopoietic stem cell transplantation (HSCT), immune-mediated bone marrow failure, and autoimmune diseases. Although highly efficacious as an immunosuppressive agent, its use is associated with clinically significant cardiovascular and metabolic adverse effects, most prominently hypertension and hyperlipidemia. These adverse effects arise through well-characterized mechanisms, including renal vasoconstriction, endothelial dysfunction, and alterations in lipid metabolism. Advanced practice providers (APPs) play a crucial role in the longitudinal care of patients receiving cyclosporine and must possess a comprehensive understanding of these complications to optimize patient outcomes. While CsA also has notable effects of nephrotoxicity, hepatotoxicity, and neurotoxicity, these will not be discussed in this review. Synthesizing current peer-reviewed literature, this practical guide examines the pathophysiologic mechanisms underlying CsA-induced hypertension and hyperlipidemia, outlines evidence-based monitoring strategies, and provides clinically actionable management recommendations tailored to the APP's scope of practice across oncology, transplant, and immunology settings.

Cyclosporine A (CsA), a cyclic polypeptide derived from the fungus *Tolypocladium inflatum*, revolutionized transplant medicine when it was introduced in the 1980s. By selectively inhibiting T-cell activation through calcineurin blockade, CsA dramatically improved graft survival rates in solid organ and hematopoietic stem cell transplantation (HSCT; Halloran, 2004). Additionally, CsA has found utility in treating immune-mediated conditions such as aplastic anemia and graft-vs.-host disease (GVHD), as well as autoimmune diseases such as severe psoriasis and rheumatoid arthritis.

Despite its therapeutic efficacy, CsA is associated with a significant adverse effect profile. Cardiovascular and metabolic complications, particularly hypertension (HTN) and hyperlipidemia (HLD), occur with high frequency and contribute significantly to long-term morbidity and mortality in transplant recipients and other patient populations requiring chronic immunosuppression (Ojo, 2006). Cardiovascular disease remains the leading cause of mortality in kidney transplant recipients, with immunosuppression representing a key modifiable contributor to this burden (Rangaswami et al., 2019). Post-transplant dyslipidemia driven by calcineurin inhibitors, particularly CsA, continues to be recognized as a current clinical challenge requiring active management (Rangaswami et al., 2019). Advanced practice providers (APPs), who often provide the majority of longitudinal care for these patients, must maintain comprehensive knowledge of these potential complications to successfully implement appropriate monitoring and management strategies.

This guide provides a comprehensive overview of CsA-induced HTN and HLD, focusing on practical clinical applications relevant to APPs in oncology, transplant, and immunology clinical practice.

MECHANISMS OF CYCLOSPORINE-INDUCED HYPERTENSION

Hypertension develops in 50% to 80% of patients receiving CsA, with the incidence varying based on dose, duration of therapy, and patient-specific factors (Curtis, 1992; Textor et al., 1994). The pathophysiology is multifactorial, involving both renal and extrarenal mechanisms (Table 1), including renal vasoconstriction and sodium retention, sympathetic nervous system activation, endothelial dysfunction, and direct effects on vascular smooth muscle.

Renal Vasoconstriction and Sodium Retention

The primary mechanism of CsA-induced hypertension involves direct renal effects. Cyclosporine A causes preferential afferent arteriolar vasoconstriction in the kidneys, mediated by several pathways (Textor et al., 1994):

- Increased endothelin-1 production, a potent vasoconstrictor
- Decreased nitric oxide bioavailability, impairing vasodilation (Vaziri et al., 1998)
- Suppression of vasodilating prostaglandins such as prostacyclin

This vasoconstriction decreases renal blood flow and glomerular filtration rate and impairs sodium excretion (Textor et al., 1994). The resulting sodium and water retention, combined with increased peripheral vascular resistance, elevates blood pressure. Notably, these effects are dose-dependent and may be partially reversible with dose reduction.

Sympathetic Nervous System Activation

Cyclosporine A enhances sympathetic nervous system activity through central and peripheral mechanisms (Textor et al., 1994). Increased sympathetic tone contributes to vasoconstriction, elevated cardiac output, and sodium retention. Cyclosporine A's effects on sympathetic activation remain controversial. Using microneurography, Scherrer et al. (1990) demonstrated increased muscle sympathetic nerve activity in CsA-treated heart transplant recipients compared to those not receiving CsA. However, subsequent studies using similar techniques found no increase in sympathetic discharge despite documented hypertension and renal vasoconstriction (Kaye et al., 1993). Spectral analysis of heart rate variability has revealed altered autonomic modulation in transplant recipients receiving cyclosporine (Lucini et al., 2000).

Endothelial Dysfunction

Cyclosporine A impairs endothelial function through multiple mechanisms that compromise vascular homeostasis. Studies have demonstrated reduced nitric oxide synthase expression in both renal and vascular tissues of CsA-treated animals, resulting in decreased production of nitric oxide, a critical endothelium-derived vasodilator (Vaziri et al., 1998). CsA appears to alter the cholesterol content of endothelial caveolae, which blunts shear stress-induced activation of endothelial nitric oxide synthase and the vasodilation that normally follows (Lungu et al., 2004). Additionally, CsA induces oxidative stress through increased superoxide and peroxynitrite formation, leading to endothelial cell damage and cytolysis (Navarro-Antolín et al., 2007). The combination of increased reactive oxygen species production and impaired

Table 1. Mechanisms of Cyclosporine-Induced Hypertension

Mechanism	Key features
Renal vasoconstriction	Afferent arteriolar constriction, decreased GFR, sodium retention, increased endothelin-1, decreased nitric oxide
Sympathetic activation	Enhanced sympathetic nervous system activity, increased heart rate variability, elevated catecholamine levels
Endothelial dysfunction	Reduced nitric oxide synthase activity, increased oxidative stress, endothelial cell apoptosis, impaired flow-mediated dilation
Vascular smooth muscle effects	Increased intracellular calcium, enhanced transmembrane calcium influx, upregulated angiotensin II receptors, enhanced vascular contractility

Note. GFR = glomerular filtration rate. Adapted from Textor et al. (1994); Scherrer et al. (1990); Kaye et al. (1993); Vaziri et al. (1998); Meyer-Lehnert & Schrier (1989); Avdonin et al. (1999).

nitric oxide bioavailability creates a state of endothelial dysfunction that contributes to both acute vasoconstriction and chronic vascular complications. In vitro studies have further demonstrated that CsA exerts antiproliferative and proapoptotic effects on human endothelial cells, suggesting direct cellular toxicity (Esposito et al., 2000). These changes contribute not only to acute blood pressure elevation but also to long-term cardiovascular complications including accelerated atherosclerosis.

Direct Effects on Vascular Smooth Muscle

Cyclosporine A exerts direct effects on vascular smooth muscle cells, contributing to vasoconstriction independent of neurohumoral mechanisms. Studies using cultured vascular smooth muscle cells demonstrated that CsA significantly increases intracellular calcium in response to arginine vasopressin (Meyer-Lehnert & Schrier, 1989). This effect involved both increased release of calcium from intracellular stores and increased calcium uptake from the extracellular space. Notably, the enhanced uptake was not blocked by the calcium channel antagonist verapamil, suggesting a mechanism distinct from voltage-gated calcium channel activation (Meyer-Lehnert & Schrier, 1989). Additionally, CsA upregulates angiotensin II receptor expression in vascular smooth muscle cells, nearly doubling receptor number without changing affinity, which amplifies the cellular calcium response to angiotensin II (Avdonin et al., 1999).

These direct effects on vascular smooth muscle result in increased vascular tone and contractility that occur independently of systemic vasoconstrictor systems and contribute to the sustained elevation in peripheral vascular resistance characteristic of CsA-induced hypertension.

MECHANISMS OF CYCLOSPORINE-INDUCED HYPERLIPIDEMIA

Hyperlipidemia occurs in 60% to 80% of cyclosporine-treated patients, typically manifesting as elevated total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides (Ballantyne et al., 1992; Kobashigawa & Kasiske, 1997). The metabolic derangements are complex and involve alterations in lipoprotein synthesis, clearance, and metabolism (Table 2).

Impaired LDL Receptor Function

The primary mechanism of CsA-induced HLD is thought to involve impaired hepatic LDL receptor-mediated clearance of LDL particles (Kobashigawa & Kasiske, 1997). This impaired clearance leads to accumulation of LDL cholesterol in circulation. Notably, in an animal model, CsA did not significantly change hepatic LDL receptor levels but markedly reduced cholesterol 7α-hydroxylase, suggesting that decreased cholesterol catabolism may contribute as much as receptor effects (Vaziri et al., 2000).

Increased Lipoprotein Synthesis

Cyclosporine A has also been associated with increased hepatic production of very-low-density-lipoprotein (VLDL) particles, the precursors to LDL (Kobashigawa & Kasiske, 1997). Increased production, combined with impaired clearance, may create a double burden contributing to elevated LDL and triglyceride levels.

Table 2. Mechanisms of Cyclosporine-Induced Hyperlipidemia

Mechanism	Key features
Reduced LDL receptor activity	Impaired hepatic LDL receptor-mediated clearance, reduced LDL clearance
Increased VLDL production	Increased hepatic VLDL production
Altered bile acid metabolism	Inhibited cholesterol 7α-hydroxylase, decreased bile acid synthesis, reduced cholesterol catabolism, altered enterohepatic circulation
Lipoprotein lipase inhibition	Reduced triglyceride hydrolysis, impaired clearance of VLDL and chylomicrons, hypertriglyceridemia

Note. LDL = low-density lipoprotein; VLDL = very-low-density lipoprotein. Adapted from Kobashigawa & Kasiske (1997); Ballantyne et al. (1992); Vaziri et al. (2000).

Altered Bile Acid Metabolism

Cyclosporine A interferes with bile acid metabolism and enterohepatic circulation. By inhibiting the expression of cholesterol 7α-hydroxylase, the rate-limiting enzyme in bile acid synthesis, CsA reduces conversion of cholesterol to bile acids (Vaziri et al., 2000). This decreased cholesterol catabolism contributes to hypercholesterolemia. Additionally, altered bile acid composition may affect intestinal cholesterol absorption.

Lipoprotein Lipase Inhibition

Cyclosporine A reduces lipoprotein lipase expression in skeletal muscle and adipose tissue, the enzyme responsible for hydrolysis of triglycerides in VLDL and chylomicrons (Vaziri et al., 2000). Decreased lipoprotein lipase function impairs clearance of triglyceride-rich lipoproteins, contributing to hypertriglyceridemia. This effect appears more pronounced at higher CsA doses.

MONITORING STRATEGIES

Systematic monitoring is essential for early detection and management of CsA-related complications. Advanced practice providers should implement comprehensive surveillance protocols that balance thoroughness with patient burden (Table 3).

Cyclosporine Therapeutic Drug Monitoring

Trough levels remain the standard for CsA monitoring. Blood samples should be obtained immediately before the morning dose. Target trough levels vary by indication:

- Solid organ transplant (early): 200–400 ng/mL
- Solid organ transplant (maintenance): 100–200 ng/mL
- Hematopoietic stem cell transplant: 200–400 ng/mL (GVHD prophylaxis)
- Aplastic anemia: 200–400 ng/mL
- Autoimmune conditions: Variable, typically 100–200 ng/mL (Novartis, 2015)

Monitoring frequency should be weekly during dose titration, then monthly once stable. More frequent monitoring is warranted with dose changes, drug interactions, or clinical instability.

Some centers utilize C2 levels (2-hour post-dose) for CsA monitoring, as C2 demonstrates better correlation with area under the curve (AUC) than trough levels. However, a systematic review found that C2 monitoring has not been widely adopted due to practical challenges of obtaining timed blood draws, lack of clear superiority in clinical outcomes such as rejection rates or renal function, and overall poor quality of evidence supporting its routine use (Knight & Morris, 2007).

Blood Pressure Monitoring

Blood pressure should be assessed at every clinical encounter. Target blood pressure for most CsA-treated patients is less than 130/80 mmHg (Whelton et al., 2018).

Home blood pressure monitoring provides valuable data on blood pressure variability and helps identify white-coat or masked hypertension. Instruct patients to measure blood pressure at consistent times, ideally in the morning and evening, and maintain a log. Ambulatory blood pressure monitoring may be considered for patients with apparent treatment-resistant hypertension or significant variability.

Table 3. Recommended Monitoring Schedule for Patients on Cyclosporine

Parameter	Initial/Titration phase	Stable/Maintenance phase
Cyclosporine trough level	Weekly	Monthly
Blood pressure	Every visit, home monitoring	Every visit, home monitoring
Lipid panel	Baseline, then 1–2 months	Every 3–6 months
Serum creatinine/eGFR	Weekly, then monthly	Every 3 months
Urinalysis	Baseline, then monthly	Every 3 months
Serum magnesium	Monthly	Monthly to quarterly
Serum potassium	Weekly to monthly	Every 3 months (more frequently if on RAAS inhibitors)

Note. eGFR = estimated glomerular filtration rate; RAAS = renin-angiotensin-aldosterone system. Adapted from KDIGO (2009); Mangray & Vella (2011); Novartis (2015).

Lipid Panel Monitoring

Obtain a baseline fasting lipid panel prior to initiating CsA when possible. Repeat lipid assessment 1 to 2 months after starting therapy or after significant dose changes. Once stable, monitor lipids every 3 to 6 months, or more frequently if abnormal or if lipid-lowering therapy is initiated. The KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients recommends measuring a complete lipid profile at least annually in all adult transplant recipients (KDIGO, 2009).

A complete lipid panel should include total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Calculate non-HDL cholesterol (total cholesterol minus HDL) as this provides a better assessment of atherogenic lipoproteins, particularly when triglycerides are elevated. For patients with triglycerides greater than 400 mg/dL, direct LDL measurement or alternative calculations may be necessary.

Renal Function Assessment

Monitor serum creatinine and estimated glomerular filtration rate (eGFR) at baseline, weekly during initiation, then monthly during the first 3 months, and every 3 months thereafter. More frequent assessment is warranted with rising creatinine, addition of nephrotoxic agents, or clinical concerns.

Urinalysis should be performed at least quarterly to assess for proteinuria, which serves as an early and sensitive marker of CsA-induced nephrotoxicity. Proteinuria may appear before significant elevations in serum creatinine and can indicate glomerular or tubular damage from CsA. In transplant recipients, even minimal proteinuria is associated with significantly worse graft outcomes. A study of 272 kidney transplant recipients found a 5-year graft survival of 97.1% in patients without proteinuria (< 0.2 g/day), compared with 83.0% with minimal proteinuria (0.2–0.5 g/day) and 70% with overt proteinuria (≥ 0.5 g/day), demonstrating a dose-dependent relationship between proteinuria and graft loss (Kang et al., 2009). Early detection of proteinuria allows timely intervention, including CsA dose adjustment or nephrology consultation, potentially preventing progression to irreversible chronic nephropathy. Quantify significant proteinuria with urine protein-to-creatinine ratio or 24-hour urine collection. Additionally, monitor serum magnesium monthly, as CsA commonly causes renal magnesium wasting. Serum potassium should be checked regularly, particularly if renin-angiotensin-aldosterone system (RAAS) inhibitors are used for blood pressure control.

Additional Monitoring Considerations

Evaluate for end-organ damage with baseline and periodic assessments (Whelton et al., 2018). Consider echocardiography for patients with poorly controlled hypertension or known cardiac disease. Fundoscopic examination or retinal photography may identify hypertensive retinopathy. For patients with proteinuria or declining renal function, nephrology consultation and consideration of renal biopsy may be appropriate to distinguish CsA nephrotoxicity from other pathology.

MANAGEMENT OF CYCLOSPORINE-INDUCED HYPERTENSION

A systematic approach to hypertension management in CsA-treated patients requires consideration of drug interactions, underlying mechanisms, and individual patient factors. The goal is to achieve target blood pressure while maintaining adequate immunosuppression and minimizing adverse effects. Table 4 summarizes the pharmacological management strategies for CsA-induced hypertension.

Lifestyle Modifications

Although pharmacologic therapy is usually required, lifestyle interventions provide additive benefit and should be emphasized for all patients with hypertension (Whelton et al., 2018):

- Sodium restriction to less than 2,300 mg daily, with consideration of more stringent limits (less than 1,500 mg) for resistant hypertension
- Weight management through caloric restriction and increased physical activity as tolerated
- Regular aerobic exercise (at least 150 minutes of moderate-intensity activity weekly)
- Alcohol moderation (no more than 1–2 drinks daily)
- Smoking cessation counseling and support

Pharmacologic Management

Calcium Channel Blockers: First-Line Therapy

Dihydropyridine calcium channel blockers (CCBs) are the preferred first-line agents for CsA-induced hypertension (Mangray & Vella, 2011). These medications directly counteract CsA-mediated vasoconstriction by dilating the afferent arteriole. In a randomized, double-blind trial of 38 heart transplant recipients receiving CsA, amlodipine (2.5 mg daily) started shortly after transplantation, maintained normal blood pressure and prevented renal deterioration during the first year compared with placebo (Leenen et al., 2007). Other dihydropyridine CCBs (nifedipine extended-release, felodipine) share the same mechanism and provide reasonable alternatives based on class effect, particularly when amlodipine is not tolerated or patient-specific factors favor once-daily extended-release formulations.

Recommended agents:

- Amlodipine 2.5–10 mg daily (preferred; strongest evidence in CsA-treated patients)
- Nifedipine extended-release 30–90 mg daily (alternative DHP-CCB)
- Felodipine 2.5–10 mg daily (alternative DHP-CCB)

Monitoring guidelines:

- Critical caution: avoid non-dihydropyridine CCBs (diltiazem, verapamil), as these potently inhibit CYP3A4 and can significantly increase CsA levels, with studies demonstrating diltiazem increasing cyclosporine AUC by approximately 50% to 60%, leading to potential toxicity (Bleck et al., 1996; Asberg et al., 1999).
- If a patient is already receiving diltiazem or verapamil with CsA, do not discontinue without adjusting CsA dose, as levels will drop precipitously.

Renin-Angiotensin-Aldosterone System Inhibitors

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs) are effective antihypertensives and provide additional renoprotection, particularly valuable in patients with proteinuria (Cross et al., 2009; Momoniat et al., 2019). However, their use requires careful monitoring due to increased risk of hyperkalemia and acute kidney injury, especially when combined with calcineurin inhibitors like CsA.

Recommended agents:

- Lisinopril 5–40 mg daily
- Losartan 25–100 mg daily
- Valsartan 80–320 mg daily

Monitoring guidelines include checking serum creatinine and potassium within 1 to 2 weeks of initiation or dose escalation. Small increases in creatinine (up to 30% from baseline) are acceptable if blood pressure improves and remains stable; discontinue if creatinine rises more than 30% or potassium exceeds 5.5 mEq/L despite intervention. Patients should avoid potassium supplements and potassium-sparing diuretics (Whelton et al., 2018).

Diuretics

Thiazide and thiazide-like diuretics are effective additions for patients with volume-dependent hypertension or those requiring multiple agents.

Table 4. Pharmacological Management of Cyclosporine-Induced Hypertension

Drug Class	Agents and dosing	Key considerations
Lifestyle modifications	Na < 2,300 mg/d; weight mgmt; exercise ≥ 150 min/wk; alcohol moderation; smoking cessation	Additive benefit to pharmacologic therapy.
CCBs (dihydropyridines)	Amlodipine 2.5–10 mg/d (preferred); nifedipine XL 30–90 mg/d; felodipine 2.5–10 mg/d	First-line; dilates afferent arteriole. Amlodipine: strongest evidence (prevented HTN and renal decline in RCT); other DHP-CCBs reasonable alternatives based on class effect.
Non-DHP CCBs	AVOID: Diltiazem, verapamil	CYP3A4 inhibitors; ↑ CsA ~50–60%; toxicity risk. If already on, adjust CsA dose before stopping.
ACE-I/ARBs	Lisinopril 5–40 mg/d; losartan 25–100 mg/d; valsartan 80–320 mg/d	Renoprotection with proteinuria. Monitor K^+, SCr in 1–2 wks. Risk: hyperkalemia, AKI.
Thiazide diuretics	Chlorthalidone 12.5–25 mg/d (preferred per general HTN guidelines); HCTZ 12.5–25 mg/d; Indapamide 1.25–2.5 mg/d	CNIs activate NCC; thiazides counter this. Chlorthalidone preferred for longer half-life (general HTN data; no head-to-head in CsA patients). Monitor Mg^{2+} (CsA causes wasting), K^+.
Loop diuretics	Furosemide 20–80 mg/d; Torsemide 5–20 mg/d	For eGFR < 30 (thiazides ineffective); monitor electrolytes.
Beta-blockers	Metoprolol 25–200 mg/d; Carvedilol 3.125–25 mg BID; Atenolol 25–100 mg/d	Not first-line. Use for CAD, HFrEF, arrhythmias. Carvedilol may ↑ CsA levels.
CsA dose optimization	10%–20% reduction OR 50% if stable > 12 mo post-transplant	For refractory HTN. Requires transplant team collaboration. 50% reduction safe without ↑ rejection.
Alternative immunosuppression	Tacrolimus, sirolimus, mycophenolate-based regimens	For severe HTN/nephrotoxicity. Tacrolimus: less HTN than CsA in meta-analysis (heart and liver transplant); higher NODAT risk.
Resistant HTN	BP above goal on 3 drugs (incl diuretic) OR controlled on ≥ 4 drugs	Evaluate adherence, secondary causes, home BP, interfering meds (NSAIDs). Refer nephrology/cardiology.

Note. ACE-I = angiotensin-converting enzyme inhibitor; AKI = acute kidney injury; ARB = angiotensin receptor blocker; BID = twice daily; BP = blood pressure; CAD = coronary artery disease; CCB = calcium channel blocker; CNI = calcineurin inhibitor; CsA = cyclosporine; CYP3A4 = cytochrome P450 3A4; DHP = dihydropyridine; eGFR = estimated glomerular filtration rate (mL/min/1.73m^2); HCTZ = hydrochlorothiazide; HFrEF = heart failure with reduced ejection fraction; HTN = hypertension; K^+ = potassium; Mg^{2+} = magnesium; NCC = sodium chloride cotransporter; NODAT = new-onset diabetes after transplantation; NSAID = nonsteroidal anti-inflammatory drug; SCr = serum creatinine; TAC = tacrolimus; XL = extended release; wk = week. Adapted from Leenen et al. (2007); Bleck et al. (1996); Asberg et al. (1999); Cross et al. (2009); Momoniat et al. (2019); Hoorn et al. (2011); Tantisattamo et al. (2020); Bader et al. (2005); Whelton et al. (2018); Carey et al. (2018); Pascual et al. (2003); Penninga et al. (2010); Muduma et al. (2016).

These medications are particularly rational for CsA-induced HTN as calcineurin inhibitors activate the thiazide-sensitive sodium chloride cotransporter (NCC) in the distal tubule, directly addressing the sodium retention component of CsA-induced HTN (Hoorn et al., 2011; Tantisattamo et al., 2020).

Recommended agents:

- Chlorthalidone 12.5–25 mg daily (preferred based on general HTN guidelines for longer duration of action)
- Hydrochlorothiazide 12.5–25 mg daily (most commonly prescribed thiazide in clinical practice)
- Indapamide 1.25–2.5 mg daily (thiazide-like with favorable metabolic profile)

Monitoring guidelines:

- Monitor electrolytes regularly, as thiazides can exacerbate CsA-induced hypomagnesemia and may cause hypokalemia.

- Magnesium supplementation is often required.
- Loop diuretics (furosemide, torsemide) may be necessary for patients with significant renal impairment (eGFR less than 30 mL/min/1.73m^2) where thiazides lose efficacy.
- Avoid potassium-sparing diuretics (spironolactone, amiloride, triamterene) due to high risk of hyperkalemia when combined with CsA.

Beta-Blockers

While not typically first-line for CsA-induced hypertension, beta-blockers are useful in patients with compelling indications such as coronary artery disease, heart failure with reduced ejection fraction, or arrhythmias. Beta-blockers are commonly used after cardiac transplantation; however, carvedilol has been associated with increased CsA levels in this population, so CsA levels should be monitored after initiation (Bader et al., 2005).

Recommended agents:

- Metoprolol succinate 25–200 mg daily
- Carvedilol 3.125–25 mg twice daily (added alpha-blockade may provide additional benefit; may increase CsA levels)
- Atenolol 25–100 mg daily

Cyclosporine Dose Optimization

When hypertension proves difficult to control despite multiple antihypertensive agents, consider CsA dose reduction in collaboration with the prescribing physician or transplant team. Prospective studies have demonstrated that 50% CsA dose reductions in stable transplant recipients can improve blood pressure without increased rejection risk (Pascual et al., 2003). Even modest reductions (10–20%) can improve blood pressure control while maintaining adequate immunosuppression.

For patients with persistent, severe HTN or significant nephrotoxicity, conversion to alternative immunosuppressive regimens may be necessary. Meta-analyses of randomized trials comparing tacrolimus with CsA as primary immunosuppression have found less HTN with tacrolimus in both heart transplant recipients (RR 0.80 for tacrolimus vs. CsA; 95% CI 0.69–0.93) and liver transplant recipients (RR 1.26 for CsA vs. tacrolimus; 95% CI 1.07–1.47), as well as less hyperlipidemia, although tacrolimus carries a higher risk of new-onset diabetes (Penninga et al., 2010; Muduma et al., 2016). Other options include sirolimus or mycophenolate-based protocols. Such decisions require multidisciplinary discussion and should account for the specific clinical indication, risk of rejection or disease flare, and individual patient comorbidities.

Resistant Hypertension

Resistant hypertension, defined as blood pressure above goal despite optimal doses of three antihypertensive agents of different classes including a diuretic, or blood pressure controlled on four or more medications, warrants systematic evaluation (Carey et al., 2018). Consider:

- Medication adherence assessment
- Review of concomitant medications that may raise blood pressure (NSAIDs, decongestants, corticosteroids)
- Evaluation for secondary causes (renal artery stenosis, primary aldosteronism, sleep apnea)
- Home and ambulatory blood pressure monitoring to exclude white-coat effect
- Nephrology or cardiology consultation for additional management strategies

MANAGEMENT OF CYCLOSPORINE-INDUCED HYPERLIPIDEMIA

Hyperlipidemia management in CsA-treated patients requires balancing cardiovascular risk reduction against the heightened potential for statin-related adverse effects due to drug interactions (Grundy et al., 2019). Treatment decisions should be guided by overall cardiovascular risk assessment and lipid targets based on current guidelines. Table 5 summarizes the pharmacological management strategies for CsA-induced hyperlipidemia.

Cardiovascular Risk Assessment

Calculate 10-year ASCVD risk using validated tools (e.g., Pooled Cohort Equations). Transplant recipients have elevated cardiovascular risk not fully captured by traditional calculators (Ojo, 2006).

Treatment thresholds:

- LDL ≥ 190 mg/dL: Statin regardless of risk
- Known ASCVD or diabetes: Statin therapy; consider adding nonstatin therapy (e.g. ezetimibe) if LDL remains ≥ 70 mg/dL in very high risk ASCVD

Table 5. Pharmacological Management of Cyclosporine-Induced Hyperlipidemia

Drug class	Agents and dosing	Key considerations
Lifestyle modifications	Dietary fat reduction; physical activity; weight mgmt; smoking cessation	Foundation of lipid management; often insufficient alone.
Statins	Preferred: Pravastatin 10–20 mg/d; fluvastatin 20–40 mg/d Caution: Atorvastatin ≤ 10 mg/d; rosuvastatin ≤ 5 mg/d AVOID: Simvastatin, lovastatin	Pravastatin/Fluvastatin: Minimal CYP3A4 metabolism, safer. Simvastatin/Lovastatin: CONTRAINDICATED (severe rhabdomyolysis risk). Atorvastatin/ Rosuvastatin: Use lowest doses only. Monitor CK, LFTs, myalgia.
Cholesterol absorption inhibitor	Ezetimibe 10 mg/d	No CYP3A4 interaction. Safe alternative or adjunct to statins. Additive LDL lowering.
Fibric acid derivatives	Fenofibrate 48–145 mg/d AVOID gemfibrozil	For severe hypertriglyceridemia (> 500 mg/dL). Fenofibrate preferred. If combined with statin: extreme caution, close monitoring for myopathy. Gemfibrozil: high rhabdomyolysis risk with statins.
Omega-3 fatty acids	Prescription omega-3 (EPA/DHA) 2–4 g/d	For hypertriglyceridemia. No significant drug interactions. Well-tolerated adjunct.

Note. CK = creatine kinase; CsA = cyclosporine; CYP3A4 = cytochrome P450 3A4; d = day; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; LDL = low-density lipoprotein; LFT = liver function test; mgmt = management. Adapted from Grundy et al. (2019); Holdaas et al. (2003); Neuvonen et al. (2006); Wiggins et al. (2016).

- 10-year ASCVD risk ≥ 7.5%: Consider statin with shared decision-making
- Transplant recipients: Consider statin given elevated baseline risk

Lifestyle Modifications

Therapeutic lifestyle changes form the foundation of lipid management (Grundy et al., 2019):

- Adopt a heart-healthy diet emphasizing fruits, vegetables, whole grains, lean proteins, and healthy fats
- Limit saturated fat to less than 7% of total calories
- Increase soluble fiber intake (10–25 grams daily)
- Achieve and maintain healthy body weight (BMI less than 25 kg/m^2)
- Engage in regular aerobic exercise (at least 150 minutes weekly)
- Smoking cessation

Pharmacologic Management

Statin Therapy: Critical Considerations

Statins remain the cornerstone of lipid-lowering therapy, but their use with CsA requires heightened vigilance due to significant pharmacokinetic interactions (Neuvonen et al., 2006). Cyclosporine A inhibits OATP1B1 and CYP3A4, dramatically increasing statin exposure and myopathy risk.

Preferred statins (lower interaction risk):

- Pravastatin 10–20 mg daily (hydrophilic, not metabolized by CYP3A4; start at 10 mg; do not exceed 20 mg daily with CsA)
- Fluvastatin 20–40 mg daily (metabolized by CYP2C9; start at 20 mg; do not exceed 20 mg twice daily with CsA; demonstrated safety in transplant recipients; Holdaas et al., 2003)

Use with extreme caution (increased myopathy risk):

- Atorvastatin: FDA labeling advises avoiding use with CsA; if used, do not exceed 10 mg daily (cyclosporine increases levels 8-fold; Wiggins et al., 2016)
- Rosuvastatin: Do not exceed 5 mg daily (cyclosporine increases levels 7-fold)

CONTRAINDICATED:

- Simvastatin (contraindicated with CsA in FDA labeling due to severe myopathy/ rhabdomyolysis risk)

Monitoring for statin-treated patients (Grundy et al., 2019):

- Baseline creatine kinase (CK) and liver transaminases (ALT, AST)
- Repeat liver enzymes at 12 weeks, then annually if normal
- Check CK if symptoms develop (unexplained muscle pain, weakness, or dark urine)
- Educate patients to report muscle symptoms immediately

Discontinue statin if CK exceeds 10 times upper limit of normal, or if symptomatic with CK elevation greater than 5 times upper limit of normal. For transaminase elevations greater than 3 times upper limit of normal, hold statin and investigate other causes before considering rechallenge.

Ezetimibe: An Excellent Alternative

Ezetimibe 10 mg daily is a valuable option for CsA-treated patients (Grundy et al., 2019). It reduces LDL cholesterol by approximately 15% to 20% through selective inhibition of intestinal cholesterol absorption. Critically, ezetimibe has no significant drug interaction with CsA and carries minimal adverse effect risk.

Ezetimibe can be used as monotherapy for patients who cannot tolerate statins, or in combination with low-dose statins to achieve lipid targets while minimizing statin exposure. The combination approach is particularly useful in CsA-treated patients where statin doses must be limited.

Fibrates: Use with Extreme Caution

Fibrates are generally avoided in CsA-treated patients due to markedly increased myopathy risk when combined with statins (Grundy et al., 2019). When severe hypertriglyceridemia (triglycerides greater than 500 mg/dL) necessitates fibrate therapy to prevent pancreatitis:

- Fenofibrate is preferred over gemfibrozil (lower interaction risk)
- Discontinue statin therapy during fibrate treatment
- Monitor CK and renal function closely (at least monthly)
- Consider alternative approaches for triglyceride management (omega-3 fatty acids, CsA dose reduction)

Omega-3 Fatty Acids

High-dose omega-3 fatty acids (EPA/DHA) can reduce triglycerides by 20% to 30% and represent a safe option for CsA-treated patients (Grundy et al., 2019). Prescription formulations include:

- Icosapent ethyl 2 grams twice daily (purified EPA)
- Omega-3 acid ethyl esters 4 grams daily
- Over-the-counter fish oil supplements (at least 3–4 grams EPA/DHA daily)

Cyclosporine Dose Optimization for Lipid Control

As with HTN, CsA dose reduction can improve lipid parameters. Advanced practice providers should work with the transplant team or primary prescriber to identify the minimum effective CsA dose. Conversion to alternative immunosuppressive regimens may be considered for patients with severe, refractory hyperlipidemia.

CRITICAL DRUG INTERACTIONS

Cyclosporine A is a substrate and inhibitor of CYP3A4 and P-glycoprotein, leading to extensive drug interaction potential (Novartis, 2015). Advanced practice providers must maintain vigilance for interactions that could increase CsA toxicity or reduce immunosuppressive efficacy (Table 6).

Agents That Increase Cyclosporine Levels

CYP3A4 and P-glycoprotein inhibitors increase CsA exposure, potentially causing nephrotoxicity, hypertension, and other adverse effects:

- Azole antifungals: Ketoconazole, itraconazole, voriconazole, posaconazole (may increase levels 2–3 fold)
- Macrolide antibiotics: Erythromycin, clarithromycin (azithromycin has minimal interaction)
- Calcium channel blockers: Diltiazem, verapamil (50%–100% increase)
- Protease inhibitors: Ritonavir, all boosted HIV regimens
- Other: Grapefruit juice, amiodarone, metoclopramide, oral contraceptives
- Management: Reduce CsA dose by 25%–50% when initiating potent inhibitors; monitor levels closely (within 3–5 days)

Table 6. Selected Drug Interactions With Cyclosporine

Effect	Drug classes/examples	Management
Increase cyclosporine levels	Azoles, macrolides, diltiazem/verapamil, protease inhibitors, grapefruit juice	Reduce cyclosporine dose 25%–50%; monitor levels within 3–5 days
Decrease cyclosporine levels	Rifampin, phenytoin, phenobarbital, carbamazepine, St. John's wort	Increase cyclosporine dose to maintain levels; avoid inducers when possible
Increased myopathy risk	All statins (especially simvastatin; contraindicated), fibrates	Use pravastatin/fluvastatin at lowest effective dose; monitor CK; educate on symptoms
Additive nephrotoxicity	NSAIDs, aminoglycosides, amphotericin B, acyclovir	Avoid NSAIDs; use acetaminophen; monitor renal function closely if combination unavoidable
Hyperkalemia risk	ACE inhibitors, ARBs, potassium-sparing diuretics, potassium supplements	Monitor potassium 1–2 weeks after initiation; avoid K+ supplements and K+-sparing diuretics

Note. ACE = angiotensin-converting enzyme; ARBs = angiotensin receptor blockers; CK = creatine kinase; K+ = potassium; NSAIDs = nonsteroidal anti-inflammatory drugs. Adapted from Neuvonen et al. (2006); Novartis (2015).

Agents That Decrease Cyclosporine Levels

CYP3A4 inducers reduce CsA exposure, potentially leading to subtherapeutic levels and increased risk of rejection or disease flare:

- Anticonvulsants: Phenytoin, phenobarbital, carbamazepine (may decrease levels 50%)
- Antimicrobials: Rifampin, rifabutin (avoid if possible)
- Herbal: St. John's wort (contraindicated)
- Management: Increase CsA dose as needed to maintain therapeutic levels; monitor closely; avoid inducers when possible

Nephrotoxic Drug Combinations

Avoid concurrent nephrotoxic agents when possible:

- NSAIDs (ibuprofen, naproxen, ketorolac); use acetaminophen for analgesia
- Aminoglycosides (gentamicin, tobramycin)
- Amphotericin B
- When nephrotoxic combinations are unavoidable, monitor renal function closely and consider dose adjustments

PATIENT EDUCATION AND ENGAGEMENT

Successful management of CsA-related complications requires active patient participation. Advanced practice providers should provide comprehensive education addressing:

- Medication adherence: Emphasize the critical importance of taking CsA at consistent times daily, avoiding missed or double doses
- Home blood pressure monitoring: Teach proper technique, optimal timing, and when to report elevated readings
- Warning signs: Educate patients to report severe headaches, vision changes, chest pain, muscle pain or weakness, dark urine, or signs of infection
- Drug interactions: Advise patients to inform all health-care providers about CsA therapy and avoid over-the-counter NSAIDs, grapefruit products, and St. John's wort
- Lifestyle modifications: Provide specific, actionable recommendations for diet, exercise, weight management, and smoking cessation
- Follow-up adherence: Stress the importance of regular laboratory monitoring and clinic visits even when feeling well

MULTIDISCIPLINARY COLLABORATION

Optimal care for CsA-treated patients requires coordination among multiple specialists. While the overall treatment strategy for CsA-related complications is established collaboratively between APPs and their physician colleagues, APPs operate at the forefront of day-to-day clinical management in ways that are distinct from the physician role. Advanced practice providers independently prescribe the antihypertensive agents,

lipid-lowering therapies, and supportive medications outlined in this guide within their full scope of practice as governed by state licensure and institutional credentialing. This independent prescribing authority, combined with the APP's central role as the longitudinal care provider, positions APPs to initiate therapy, adjust doses, manage drug interactions, and respond to emerging toxicities without requiring physician co-signature for each clinical decision.

Survey data suggest that APPs in hematology and oncology spend approximately 73% of their time in the outpatient setting and manage their own patient panels in the large majority of cases (Marshall et al., 2024), making them the primary point of continuity for patients on long-term CsA therapy. In contrast, physician involvement is most valuable at key decision points: establishing the immunosuppressive regimen, guiding major therapy transitions (such as conversion from CsA to tacrolimus), and managing complex cases that exceed the APP's institutional scope. This collaborative model, in which the physician defines the overarching treatment framework and the APP executes and monitors the longitudinal plan, reflects current best practices in team-based oncology and transplant care (Chambers et al., 2021; Pickard et al., 2023). Advanced practice providers often serve as central care coordinators, facilitating communication between:

- Transplant team or prescribing physician: Discuss dose adjustments, conversion strategies, and overall immunosuppression management
- Nephrology: Consult for progressive renal dysfunction, significant proteinuria, or difficult-to-control HTN
- Cardiology: Involve for resistant HTN, established cardiovascular disease, or heart failure
- Clinical pharmacy: Leverage pharmacist expertise for drug interaction assessment, dose optimization, and medication reconciliation
- Registered dietitian: Refer for medical nutrition therapy targeting cardiovascular risk reduction
- Primary care provider: Ensure coordination of overall health maintenance and comorbidity management

CONCLUSION

Hypertension and HLD represent common and clinically significant adverse effects of CsA therapy that require recognition, monitoring, and effective management from APPs. These adverse effects arise through well-defined mechanisms involving renal vasoconstriction, endothelial dysfunction, and altered lipid metabolism. An understanding of these pathophysiologic processes enables APPs to implement appropriate monitoring strategies and evidence-based interventions.

Effective management requires a comprehensive approach incorporating regular surveillance, patient education, lifestyle modification, and targeted pharmacotherapy. Drug selection must account for the complex interaction profile of CsA, particularly its increased myopathy risk with statins and the contraindication against combining it with certain calcium channel blockers. If standard interventions are inadequate, dose reduction or switching to alternative immunosuppressive therapies should be considered in collaboration with the prescribing team.

Advanced practice providers play a pivotal role in the longitudinal care of patients treated with CsA, serving as educators, care coordinators, and primary monitors for treatment-related complications. By maintaining vigilance for cardiovascular and metabolic adverse effects and collaborating with multidisciplinary specialists, APPs can help optimize both the efficacy of immunosuppressive therapy and long-term patient outcomes. As CsA remains a cornerstone immunosuppressive agent across diverse indications, expertise in managing its complications remains an essential skill for APPs in oncology, transplant, and immunology settings.

Disclosure

Ms. Geppner has served as a consultant for AbbVie, Bristol Myers Squibb, and Daiichi Sankyo.

References

Asberg, A., Christensen, H., Hartmann, A., Carlson, E., Molden, E., & Berg, K. J. (1999). Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients. *European Journal of Clinical Pharmacology, 55*(5), 383–387. https://doi.org/10.1007/s002280050644

Avdonin, P. V., Cottet-Maire, F., Afanasjeva, G. V., Loktionova, S. A., Lhote, P., & Ruegg, U. T. (1999). Cyclosporine A up-regulates angiotensin II receptors and calcium re-

sponses in human vascular smooth muscle cells. *Kidney International, 55*(6), 2407–2414. https://doi.org/10.1046/j.1523-1755.1999.00481.x

Bader, F. M., Hagan, M. E., Crompton, J. A., & Gilbert, E. M. (2005). The effect of beta-blocker use on cyclosporine level in cardiac transplant recipients. *The Journal of Heart and Lung Transplantation, 24*(12), 2144–2147. https://doi.org/10.1016/j.healun.2005.05.002

Ballantyne, C. M., Radovancevic, B., Farmer, J. A., Frazier, O. H., Chandler, L., Payton-Ross, C., Cocanougher, B., Jones, P. H., Young, J. B., & Gotto, A. M. (1992). Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. *Journal of the American College of Cardiology, 19*(6), 1315–1321. https://doi.org/10.1016/0735-1097(92)90340-S

Bleck, J. S., Thiesemann, C., Kliem, V., Christians, U., Hecker, H., Repp, H., Frei, U., Westhoff-Bleck, M., Manns, M., & Sewing, K. F. (1996). Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients. *British Journal of Clinical Pharmacology, 41*(6), 551–556. https://doi.org/10.1046/j.1365-2125.1996.34412.x

Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., Lackland, D. T., Laffer, C. L., Newton-Cheh, C., Smith, S. M., Taler, S. J., Textor, S. C., Turan, T. N., & White, W. B. (2018). Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. *Hypertension, 72*(5), e53–e90. https://doi.org/10.1161/HYP.0000000000000084

Chambers, H. E., Reinschmidt, K., Smith, G., Agudelo, E., Brodahl, K., Herriman, E., Hoy, H., Pont, K., Seawright, A., Stearns, E., Torres, A. M., Weldon, E., & Blackstock, D. M. (2021). Examining the critical role of advanced practice providers on a multidisciplinary transplant team. *American Journal of Transplantation, 21*(12), 3840–3846. https://doi.org/10.1111/ajt.16715

Cross, N. B., Webster, A. C., Masson, P., O'Connell, P. J., & Craig, J. C. (2009). Antihypertensive treatment for kidney transplant recipients. *Cochrane Database of Systematic Reviews, 2009*(3), Article CD003598. https://doi.org/10.1002/14651858.CD003598.pub2

Curtis, J. J. (1992). Cyclosporine and posttransplant hypertension. *Journal of the American Society of Nephrology, 2*(12 Suppl.), S243–S245. https://doi.org/10.1681/ASN.V212s243

Esposito, C., Fornoni, A., Cornacchia, F., Bellotti, N., Fasoli, G., Foschi, A., Mazzucchelli, I., Mazzullo, T., Semeraro, L., & Dal Canton, A. (2000). Cyclosporine induces different responses in human epithelial, endothelial and fibroblast cell cultures. *Kidney International, 58*(1), 123–130. https://doi.org/10.1046/j.1523-1755.2000.00147.x

Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., . . . Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation, 139*(25), e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625

Halloran, P. F. (2004). Immunosuppressive drugs for kidney transplantation. *The New England Journal of Medicine, 351*(26), 2715–2729. https://doi.org/10.1056/NEJMra033540

Holdaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., Grönhagen-Riska, C., Madsen, S., Neumayer, H. H., Cole, E., Maes, B., Ambühl, P., Olsson, A. G., Hartmann, A., Solbu, D. O., & Pedersen, T. R. (2003). Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. *The Lancet, 361*(9374), 2024–2031. https://doi.org/10.1016/S0140-6736(03)13638-0

Hoorn, E. J., Walsh, S. B., McCormick, J. A., Fürstenberg, A., Yang, C. L., Roeschel, T., Paliege, A., Howie, A. J., Conley, J., Bachmann, S., Unwin, R. J., & Ellison, D. H. (2011). The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. *Nature Medicine, 17*(10), 1304–1309. https://doi.org/10.1038/nm.2497

Kang, N. R., Lee, J. E., Huh, W., Kim, S. J., Kim, Y. G., Kim, D. J., & Oh, H. Y. (2009). Minimal proteinuria one year after transplant is a risk factor for graft survival in kidney transplantation. *Journal of Korean Medical Science, 24*(Suppl. 1), S129–S134. https://doi.org/10.3346/jkms.2009.24.S1.S129

Kaye, D., Thompson, J., Jennings, G., & Esler, M. (1993). Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. *Circulation, 88*(3), 1101–1109. https://doi.org/10.1161/01.CIR.88.3.1101

Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. (2009). KDIGO clinical practice guideline for the care of kidney transplant recipients. *American Journal of Transplantation, 9*(Suppl. 3), S1–S155. https://doi.org/10.1111/j.1600-6143.2009.02834.x

Knight, S. R., & Morris, P. J. (2007). The clinical benefits of cyclosporine C2-level monitoring: A systematic review. *Transplantation, 83*(12), 1525–1535. https://doi.org/10.1097/01.tp.0000268306.41196.2c

Kobashigawa, J. A., & Kasiske, B. L. (1997). Hyperlipidemia in solid organ transplantation. *Transplantation, 63*(3), 331–338. https://doi.org/10.1097/00007890-199702150-00001

Leenen, F. H. H., Coletta, E., & Davies, R. A. (2007). Prevention of renal dysfunction and hypertension by amlodipine after heart transplant. *The American Journal of Cardiology, 100*(3), 531–535. https://doi.org/10.1016/j.amjcard.2007.03.058

Lucini, D., Milani, R. V., Ventura, H. O., Mehra, M. R., Messerli, F., & Pagani, M. (2000). Study of arterial and autonomic effects of cyclosporine in humans. *Hypertension, 35*(6), 1258–1263. https://doi.org/10.1161/01.HYP.35.6.1258

Lungu, A. O., Jin, Z. G., Yamawaki, H., Tanimoto, T., Wong, C., & Berk, B. C. (2004). Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae. *Journal of Biological Chemistry, 279*(47), 48794–48800. https://doi.org/10.1074/jbc.M313897200

Mangray, M., & Vella, J. P. (2011). Hypertension after kidney transplant. *American Journal of Kidney Diseases, 57*(2),

331–341. https://doi.org/10.1053/j.ajkd.2010.10.048
Marshall, A. L., Masselink, L. E., Kouides, P. A., Davies, F. E., Farooqui, A., Nagalla, S., Herrera, A., Mortier, N., Brodsky, R., & Erikson, C. E. (2024). Advanced practice providers in hematology: Actionable findings from national paired APP and physician surveys. *Blood Advances, 8*(5), 1179–1189. https://doi.org/10.1182/bloodadvances.2023011927
Meyer-Lehnert, H., & Schrier, R. W. (1989). Potential mechanism of cyclosporine A-induced vascular smooth muscle contraction. *Hypertension, 13*(4), 352–360. https://doi.org/10.1161/01.HYP.13.4.352
Momoniat, T., Ilyas, D., & Bhandari, S. (2019). ACE inhibitors and ARBs: Managing potassium and renal function. *Cleveland Clinic Journal of Medicine, 86*(9), 601–607. https://doi.org/10.3949/ccjm.86a.18024
Muduma, G., Saunders, R., Odeyemi, I., & Pollock, R. F. (2016). Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. *PLOS ONE, 11*(11), Article e0160421. https://doi.org/10.1371/journal.pone.0160421
Navarro-Antolín, J., Redondo-Horcajo, M., Zaragoza, C., Alvarez-Barrientos, A., Fernández, A. P., León-Gómez, E., Rodrigo, J., & Lamas, S. (2007). Role of peroxynitrite in endothelial damage mediated by cyclosporine A. *Free Radical Biology and Medicine, 42*(3), 394–403. https://doi.org/10.1016/j.freeradbiomed.2006.11.008
Neuvonen, P. J., Niemi, M., & Backman, J. T. (2006). Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. *Clinical Pharmacology & Therapeutics, 80*(6), 565–581. https://doi.org/10.1016/j.clpt.2006.09.003
Novartis Pharmaceuticals Corporation. Sandimmune (cyclosporine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
Ojo, A. O. (2006). Cardiovascular complications after renal transplantation and their prevention. *Transplantation, 82*(5), 603–611. https://doi.org/10.1097/01.tp.0000235527.81917.fe
Pascual, M., Curtis, J., Delmonico, F. L., Farrell, M. L., Williams, W. W., Kalil, R., Jones, P., Cosimi, A. B., & Tolkoff-Rubin, N. (2003). A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. *Transplantation, 75*(9), 1501–1505. https://doi.org/10.1097/01.TP.0000061606.64917.BE
Penninga, L., Møller, C. H., Gustafsson, F., Steinbrüchel, D. A., & Gluud, C. (2010). Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: Systematic review with meta-analyses and trial sequential analyses of randomised trials. *European Journal of Clinical Pharmacology, 66*(12), 1177–1187. https://doi.org/10.1007/s00228-010-0902-6
Pickard, T., Williams, S., Tetzlaff, E., Petraitis, C., & Hylton, H. (2023). Team-based care in oncology: The impact of the advanced practice provider. *American Society of Clinical Oncology Educational Book, 43*, Article e390572. https://doi.org/10.1200/EDBK_390572
Rangaswami, J., Mathew, R. O., Parasuraman, R., Tantisattamo, E., Lubetzky, M., Rao, S., Yaqub, M. S., Birdwell, K. A., Bennett, W., Dalal, P., Kapoor, R., Lerma, E. V., Lerman, M., McCormick, N., Bangalore, S., McCullough, P. A., & Dadhania, D. M. (2019). Cardiovascular disease in the kidney transplant recipient: Epidemiology, diagnosis and management strategies. *Nephrology Dialysis Transplantation, 34*(5), 760–773. https://doi.org/10.1093/ndt/gfz053
Scherrer, U., Vissing, S. F., Morgan, B. J., Rollins, J. A., Tindall, R. S., Ring, S., Hanson, P., Mohanty, P. K., & Victor, R. G. (1990). Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. *The New England Journal of Medicine, 323*(11), 693–699. https://doi.org/10.1056/NEJM199009133231101
Tantisattamo, E., Molnar, M.Z., Ho, B.T., Reddy, U. G., Dafoe, D. C., Ichii, H., Ferrey, A. J., Hanna, R. M., Kalantar-Zadeh, K., & Amin, A. (2020). Approach and management of hypertension after kidney transplantation. *Frontiers in Medicine, 7*, Article 229, https://doi.org/10.3389/fmed.2020.00229
Textor, S. C., Canzanello, V. J., Taler, S. J., Wilson, D. J., Schwartz, L. L., Augustine, J. E., Raymer, J. M., Romero, J. C., Wiesner, R. H., & Krom, R. A. (1994). Cyclosporine-induced hypertension after transplantation. *Mayo Clinic Proceedings, 69*(12), 1182–1193. https://doi.org/10.1016/S0025-6196(12)65772-3
Vaziri, N. D., Ni, Z., Zhang, Y. P., Ruzics, E. P., Maleki, P., & Ding, Y. (1998). Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension. *Kidney International, 54*(2), 482–491. https://doi.org/10.1046/j.1523-1755.1998.00014.x
Vaziri, N. D., Liang, K., & Azad, H. (2000). Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. *Journal of Pharmacology and Experimental Therapeutics, 294*(2), 778–783.
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., . . . Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology, 71*(19), e127–e248. https://doi.org/10.1016/j.jacc.2017.11.006
Wiggins, B. S., Saseen, J. J., Page, R. L., II, Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D., Virani, S., & Morris, P. B. (2016). Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: A scientific statement from the American Heart Association. *Circulation, 134*(21), e468–e495. https://doi.org/10.1161/CIR.0000000000000456